PharmaVOICE - 
January 2003
Purchase Issue

In Every Issue
Talent Pool
TALENT POOL EXECUTIVE APPOINTMENTS AND PROMOTIONS IN THE HEALTHCARE INDUSTRY [...]
By
E-Media
NEW ELECTRONIC AND WEB-BASED APPLICATIONS, SITES, AND TECHNOLOGIES PatientLinx.com Offers [...]
By
What’s New
NEW HEALTHCARE-RELATED PRODUCTS, SERVICES, AND COMPANIES NOP World Health Forms [...]
By
PharmaTrax
SALES, MARKETING, AND R&D TRENDS AFFECTING THE HEALTHCARE INDUSTRY GENERICS [...]
By
For Art’s Sake
There are a handful of “classic” pharmaceutical healthcare ads. Ads [...]
By
PharmaOutlet
A WHOLE NEW MEANING TO JUNK MAIL If you are [...]
By

Brian P. Waldman

PharmaCase
Making a case for PATIENT EDUCATION Patient ed project puts [...]
By
What’s on your mind: Opinions
OPINIONS Information standards In the November/December issue of PharmaVOICE, we [...]
By
Raise Your Voice: Letters
LETTERS Two critical areas of success Missed Opportunities Your article [...]
By
Letter from the Editor
Funding in a closed space The healthcare private equity market [...]
By

Taren Grom, Editor

On The Cover

Venture Capital: Funding Challenges
VENTURE CAPITAL: CAUTIOUS investment Venture capital firms are sitting on massive funds and are still doing deals, but their energies are focused on reinvesting in portfolio companies and safer latest age deals. As a result, it has never been harder for the early stage pure startup to get funded. IN THE VAULT … KEN ANDERSEN. [...]
By

Taren Grom, Editor

Features

Dr. Donald G. Payan — Reaching for the Stars Through Molecules
As cofounder, executive VP, and chief scientific officer of Rigel Pharmaceuticals, Dr. Donald G. Payan intends to have his company become the brightest star among those hunting for new drugs. LIFE’S BIGGEST DECISIONS OFTEN CAN BE ATTRIBUTED TO COINCIDENCE. In the mid-1960s, Dr. Payan arrived in California to study physics and math at Stanford University, [...]
By

Taren Grom, Editor

Addressing Pharma’s $40 Billion Challenge
Michael Perry, Ph.D., president and CEO, and Arthur Reidel, chairman, of Pharsight, outline the potential solutions and describe the remaining obstacles to successful implementation of technology as a way to unclog the pipeline.
By
A Community Approach
As many pharmaceutical companies are finding, healthcare begins within the community, and a regional program, with health information that helps patients at a local level, might just win a company the hearts, minds, and ultimately buying power of those community members. For an industry confronted with heavy regulations and intense competition, finding ways to develop [...]
By

Kim Ribbink

Delivering on the Promise
BY ELISABETH PENA Drug delivery promises FULLER PIPELINES, EXTENDED PRODUCT LIFE CYCLES, and IMPROVED PATIENT COMPLIANCE. AS THE PHARMACEUTICAL INDUSTRY FACES A FLOOD OF BLOCKBUSTER DRUG PATENT EXPIRATIONS, drug-delivery COMPANIES WILL HAVE THE CHANCE TO PROVE THEMSELVES. BY 2005 analysts predict that 20% of all pharmaceuticals will involve drug-delivery formulations. Frost & Sullivan estimated the [...]
By

Elisabeth Pena

FEEDBACK